within Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AA02_Chlortetracycline;

model Chlortetracycline
  extends Pharmacolibrary.Drugs.ATC.D.D06AA02
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.3,
    Cl             = 6.666666666666666e-07,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Chlortetracycline</td></tr><tr><td>ATC code:</td><td>D06AA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>40</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Chlortetracycline is a broad-spectrum tetracycline antibiotic primarily used for topical treatment of skin infections and for veterinary purposes. It was formerly used systemically in humans but is now largely replaced by other tetracyclines. Currently, its main human use is in ophthalmic ointments and for superficial skin infections. Chlortetracycline is not widely used systemically in clinical human medicine today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic model for adult humans, oral route, as no dedicated human systemic PK studies with reported parameters exist. Values inferred from pharmacokinetic knowledge of tetracyclines, as no direct published PK study for chlortetracycline in humans is identified.</p><h4>References</h4><ol><li><p>Zhang, Y, et al., &amp; Yu, M (2022). Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of . <i>Microbial drug resistance (Larchmont, N.Y.)</i> 28(7) 832–840. DOI:<a href=\"https://doi.org/10.1089/mdr.2022.0008\">10.1089/mdr.2022.0008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35723674/\">https://pubmed.ncbi.nlm.nih.gov/35723674</a></p></li><li><p>Cazer, CL, et al., &amp; Gröhn, YT (2018). Expanding behavior pattern sensitivity analysis with model selection and survival analysis. <i>BMC veterinary research</i> 14(1) 355–None. DOI:<a href=\"https://doi.org/10.1186/s12917-018-1674-y\">10.1186/s12917-018-1674-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30453986/\">https://pubmed.ncbi.nlm.nih.gov/30453986</a></p></li><li><p>Cazer, CL, et al., &amp; Gröhn, YT (2017). Monte Carlo Simulations Suggest Current Chlortetracycline Drug-Residue Based Withdrawal Periods Would Not Control Antimicrobial Resistance Dissemination from Feedlot to Slaughterhouse. <i>Frontiers in microbiology</i> 8 1753–None. DOI:<a href=\"https://doi.org/10.3389/fmicb.2017.01753\">10.3389/fmicb.2017.01753</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29033901/\">https://pubmed.ncbi.nlm.nih.gov/29033901</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Chlortetracycline;
